Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v11-FR | Version v7-FR | |
|---|---|---|
| Language | French | French |
| Date Updated | 2022-11-17 | 2022-10-31 |
| Drug Identification Number | 02327813 | 02327813 |
| Brand name | GALLIUM (GA67) CITRATE INJECTION | GALLIUM (GA67) CITRATE INJECTION |
| Common or Proper name | gallium Ga-67 citrate injection | gallium Ga-67 citrate injection |
| Company Name | CURIUM CANADA INC | CURIUM CANADA INC |
| Ingredients | GALLIUM CITRATE GA 67 | GALLIUM CITRATE GA 67 |
| Strength(s) | 74MBq | 74MBq |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS | INTRAVENOUS INTRAVENOUS |
| Packaging size | 6 & 12 mCi | 6 & 12 mCi |
| ATC code | V09HX | V09HX |
| ATC description | ||
| Reason for shortage | Other (Please describe in comments) | Other (Please describe in comments) |
| Anticipated start date | 2022-10-07 | 2022-10-07 |
| Actual start date | 2022-10-07 | 2022-10-07 |
| Estimated end date | 2022-11-13 | 2022-11-06 |
| Actual end date | 2022-11-13 | |
| Shortage status | Resolved | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | Following the discontinuation of Lantheus product, Curium is unable to cover Lantheus market. Due to a cyclotron mechanical issue, Curium was unable to execute production of Ga-67 raw material. As a consequence, Gallium Citrate Ga 67 Injection will not be available for shipment Nov 6-10, 2022. | Following the discontinuation of Lantheus product, Curium is unable to cover lantheus market. Curium will continue to supply its customers with no disruption. |
| Health Canada comments |